Zhaoke Ophthalmology Limited (HKG:6622)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.150
-0.050 (-1.56%)
Apr 17, 2026, 3:53 PM HKT
Market Cap1.73B +54.4%
Revenue (ttm)35.58M -53.9%
Net Income-232.56M
EPS-0.43
Shares Out548.75M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume395,000
Average Volume504,540
Open3.240
Previous Close3.200
Day's Range3.120 - 3.270
52-Week Range1.470 - 4.600
Beta1.17
RSI52.73
Earnings DateMar 25, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 276
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6622
Full Company Profile

Financial Performance

In 2025, Zhaoke Ophthalmology's revenue was 31.97 million, a decrease of -53.88% compared to the previous year's 69.32 million. Losses were -208.98 million, -12.00% less than in 2024.

Financial numbers in CNY Financial Statements